| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Precigen, Inc.$5.32
-0.24 (-4.39%)
D 31Pipeline Score Richly Valued Biotech · Commercial
Market Cap
1.51 B
EPS
-1.24
P/E Ratio
-
Value Trade
29.30 M
SEC Financials
Q1 2026Dilution Risk
Revenue
23.25 M
R&D Expenses
5.64 M
Operating CF
-43.83 M
Total Assets
138.63 M
Total Liabilities
118.39 M
Equity
20.23 M
D/E Ratio
12,345
-6.61 %
Week
5.47 %
1 Month
-4.72 %
3 Month
9.56 %
6 Month
-38.1 %
5 Year
-79.71 %
All Time
Cash Data
Cash Position
56.25 M
Monthly Burn
14.61 M
Runway
2.2 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
3.46 M
52 Week Range
1.28 - 5.47
% held by Insiders
55.32 %
% held by Institutions
37.65 %
Enterprise Value
1.55 B
Total Shares
356.44 M
Short %
25.32 %
Float Shares
174.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Precigen, Inc.
403Total events
1Upcoming
90Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 1
Event history 402
Jun 8, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
May 30, 2026
▲Oral PresentationPAPZIMEOSApprovedPresentation
Updated long-term durability data presented at ASCO 2026
recurrent respiratory papillomatosis (RRP)source ↗
May 30, 2026
▲FDA ApprovalPAPZIMEOSApprovedFDA Decision
FDA full approval for PAPZIMEOS
recurrent respiratory papillomatosis (RRP)source ↗
May 30, 2026
▲Exclusivity GrantedPAPZIMEOSApprovedIP / Competition
Seven-year market exclusivity granted by FDA
recurrent respiratory papillomatosis (RRP)source ↗
May 27, 2026
▲Exclusivity GrantedPAPZIMEOSApprovedIP / Competition
FDA grants orphan drug exclusivity for PAPZIMEOS for RRP through August 14, 2032
recurrent respiratory papillomatosis (RRP)source ↗
May 13, 2026
Mar 31, 2026
◆Oral PresentationPresentation
Precigen to participate in virtual fireside chat with H.C. Wainwright
Jan 20, 2026
▲PublicationPAPZIMEOSApprovedPresentation
Expert consensus paper published in The Laryngoscope recommending PAPZIMEOS as first-line standard of care for RRP
recurrent respiratory papillomatosis (RRP)source ↗
Jan 15, 2026
◆Oral PresentationPresentation
Precigen presentation at 44th Annual J.P. Morgan Healthcare Conference
Drug Pipeline Intelligence
D31
Pipeline Score $109M
Pipeline ValueRichly Valued
Valuation Signal7
Drugs Scored0.1x
rNPV / MCap Top 38%
Micro Cap (rank 566 of 911)
Percentile RankPrecigen, Inc. faces pipeline headwinds (31/100), with $1.4B risk-adjusted pipeline value, led by AG019 - Low Dose in Diabetes type1 (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AG019 - Low Dose Monoclonal antibody | Diabetes type1 | Phase 1 | NCT03751007 | 26% | $625M | COMPLETED | 45 | - | - | Oct 13, 2021 | - | Feb 1, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PRGN-2012 BreakthroughPriorityAccelerated+1 | recurrent respiratory papillomatosis | Phase 1/2 | 2024-06-03 | complete response: 51% (18 out of 35); surgical interventions reduction: 86% (30 out of 35); median pre treatment surgeries: 4; median post treatment surgeries: 0; median duration of follow up: 20 months Read More | Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response – Phase 1/2 pivotal study met the primary safety and efficacy endpoints – – 51% (18 out of 35) of patients achieved Complete Response, requiring no... Read More | |
PRGN-2012 BreakthroughPriorityAccelerated+1 | recurrent respiratory papillomatosis | Phase 1/2 | 2024-06-03 | complete response: 51% (18 out of 35); surgical interventions reduction: 86% (30 out of 35); median pre treatment surgeries: 4; median post treatment surgeries: 0; median duration of follow up: 20 months Read More | Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response – Phase 1/2 pivotal study met the primary safety and efficacy endpoints – – 51% (18 out of 35) of patients achieved Complete Response, requiring no... Read More | |
PRGN-2012 BreakthroughPriorityAccelerated+1 | recurrent respiratory papillomatosis | Phase 1/2 | 2024-06-03 | complete response: 51% (18 out of 35); surgical interventions reduction: 86% (30 out of 35); median pre treatment surgeries: 4; median post treatment surgeries: 0; median duration of follow up: 20 months Read More | Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response – Phase 1/2 pivotal study met the primary safety and efficacy endpoints – – 51% (18 out of 35) of patients achieved Complete Response, requiring no... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PGEN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PGEN▲ +16.5%on this news
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Precigen and the Recurrent Respiratory Papillomatosis Foundation celebrate the third annual RRP Awareness Day, emphasizing the importance of patient voices in understanding recurrent respiratory papillomatosis (RRP). This event comes after the FDA's approval of Precigen's HPV-specific immunotherapy, the first treatment for adults with RRP. The campaign aims to raise awareness and support for those affected by this debilitating disease.
Read more →PGEN▼ -5.1%on this news
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen, Inc. announced updated long-term data for PAPZIMEOS at the 2026 ASCO Annual Meeting. The therapy, recently granted FDA approval and seven-year market exclusivity, demonstrates significant durability in treating recurrent respiratory papillomatosis (RRP). With 83% of patients showing ongoing responses, PAPZIMEOS is positioned as the new standard of care for RRP, traditionally managed through repeated surgeries.
Read more →PGENPrecigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
Precigen, Inc. announced that the FDA has granted orphan drug exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) for treating adults with recurrent respiratory papillomatosis (RRP). This exclusivity, effective until August 14, 2032, follows the full approval of PAPZIMEOS in August 2025, making it the first approved therapy for RRP. The exclusivity enhances the product's market protection and revenue potential.
Read more →PGENPrecigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
Precigen, Inc. announced its participation in two upcoming investor events, including a virtual fireside chat with J.P. Morgan and the Goldman Sachs 47th Annual Global Healthcare Conference. CEO Helen Sabzevari will represent the company at both events, highlighting its commitment to advancing precision medicines. Details about the events can be found on Precigen's website.
Read more →PGEN▲ +10.8%on this news
Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen, Inc. reported strong financial results for Q1 2026, driven by the successful launch of PAPZIMEOS, the first FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The company recognized $21.6 million in net revenue from PAPZIMEOS and is optimistic about future growth. Despite a net loss of $7.9 million, Precigen is focused on expanding its market presence and advancing its pipeline.
Read more →PGEN▼ -5.7%on this news
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
Precigen, Inc. announced it will release its first quarter 2026 financial results on May 13, 2026. The company will hold a conference call at 4:30 PM ET to discuss these results. Precigen specializes in precision medicines aimed at treating difficult diseases, with a focus on immuno-oncology and other therapeutic areas.
Read more →PGEN▼ -11.4%on this news
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
Precigen, Inc. announced that its President and CEO, Helen Sabzevari, along with Chief Commercial Officer Phil Tennant, will participate in a virtual fireside chat with H.C. Wainwright on March 31, 2026. This event aims to discuss the company's advancements in precision medicine and its robust pipeline targeting difficult-to-treat diseases. Details for the event can be found on Precigen's website.
Read more →PGEN▲ +25.5%on this newsshared move
Precigen Reports Full Year 2025 Financial Results and Business Updates
Precigen, Inc. reported its full year 2025 financial results, highlighting the FDA approval and launch of PAPZIMEOS, which has gained strong traction among physicians and patients. The company noted a significant increase in revenues driven by PAPZIMEOS sales, despite a notable rise in net loss due to non-cash items. The company anticipates reaching cash flow break-even by the end of 2026.
Read more →PGENPrecigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to...
Precigen, Inc. is set to announce its full year 2025 financial results and provide business updates on March 25. The announcement will be accessible through a conference call, with details available on the company's website. The press release includes a cautionary statement regarding forward-looking statements, highlighting potential risks and uncertainties related to the company's business strategies and the commercialization of their product, PAPZIMEOS. Stakeholders are advised to review the risk factors outlined in the company's latest Annual Report.
Read more →PGENNew Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Precigen, Inc. announced that a new expert consensus paper recommends PAPZIMEOS (zopapogene imadenovec) as the first-line treatment for adults with recurrent respiratory papillomatosis (RRP). This marks a significant shift from traditional surgical interventions to a therapy that targets the underlying HPV infection. The consensus, authored by 16 leading physicians, emphasizes the importance of early treatment and provides a clear management approach for RRP.
Read more →PGEN▼ -9.9%on this news
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in August 2025, the first-and-only FDA-approved treatment for...
Precigen has announced the successful commercialization of PAPZIMEOS, the first and only FDA-approved treatment for recurrent respiratory papillomatosis (RRP). The company has reported rapid adoption across medical centers and expanded payer access since its launch. With strong safety and efficacy data, PAPZIMEOS is projected to establish itself as the preferred first-line treatment for RRP. Furthermore, Precigen is focused on global expansion, as indicated by the European Medicines Agency validating its Marketing Authorization Application.
Read more →PGEN▲ +8.9%on this news
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Precigen, Inc. announced that its CEO, Dr. Helen Sabzevari, will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. Additionally, she will participate in a fireside chat at the Biotech Showcase on January 12, 2026. These events highlight Precigen's focus on advancing precision medicines.
Read more →PGEN▲ +25.6%on this news
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
Precigen, Inc. reported its third-quarter 2025 financial results, highlighting the FDA approval of PAPZIMEOS, the first treatment for adults with recurrent respiratory papillomatosis (RRP). The company noted strong demand and early interest in the therapy, which aims to address the root cause of RRP. However, financial results showed a significant increase in expenses and a notable net loss.
Read more →PGENPrecigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Precigen, Inc. will announce its third quarter 2025 financial results and provide business updates on November 13, 2025. A conference call is scheduled for the same day at 4:30 PM ET, accessible via specific dialing instructions. The company focuses on innovative precision medicines for difficult-to-treat diseases.
Read more →PGENPrecigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Precigen, Inc. announced long-term follow-up results showing durable responses to PAPZIMEOS, the first FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). Presented at the AAO-HNSF 2025 Annual Meeting, the data indicate that 51% of patients achieved complete response, eliminating the need for surgeries. The therapy is well-tolerated and represents a breakthrough in RRP treatment.
Read more →PGENPrecigen Announces Up to $125 Million Non-Dilutive Financing
Precigen, Inc. has announced a credit facility agreement providing up to $125 million in non-dilutive financing, aimed at enhancing its balance sheet and supporting the commercialization of its immunotherapy, PAPZIMEOS. This funding will also facilitate potential international market expansion and the pursuit of pediatric and HPV-related indications. The financing reflects Precigen's strategic growth objectives as it transitions into a commercial entity.
Read more →PGENPrecigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
Precigen, Inc. announced its participation in two virtual fireside chats hosted by Cantor and H.C. Wainwright. The discussions will focus on the recent FDA approval of a therapy for recurrent respiratory papillomatosis. Key executives from Precigen will represent the company during these events, which are accessible via their website.
Read more →PGENUS FDA Approval of PAPZIMEOS
The US FDA has granted approval for PAPZIMEOS, the first therapy specifically designed for adults with recurrent respiratory papillomatosis (RRP). This significant milestone offers patients a pioneering treatment option, potentially reducing the need for frequent surgical interventions. Clinical data indicate that the therapy achieved a 51% complete response rate, demonstrating its efficacy in managing RRP. Additionally, PAPZIMEOS has shown good tolerability with limited adverse effects, marking a transformative advancement for the RRP community.
Read more →PGEN▲ +58.9%on this news· ran to +74% by day 3shared move
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
Precigen, Inc. announced full FDA approval for PAPZIMEOS (zopapogene imadenovec-drba), the first and only therapy for adults with recurrent respiratory papillomatosis (RRP). This landmark approval allows patients to access a treatment that targets the root cause of RRP, potentially reducing the need for repeated surgeries. The therapy is delivered via four subcutaneous injections over 12 weeks, marking a significant advancement in the management of this debilitating condition.
Read more →PGENPrecigen Reports First Quarter 2025 Financial Results and Business Updates
Precigen, Inc. reported its first quarter 2025 financial results, highlighting progress in its PRGN-2012 program aimed at treating recurrent respiratory papillomatosis (RRP). The company is focused on advancing this program towards a potential FDA approval in August. Financially, Precigen ended the quarter with $81 million in cash, although it reported a significant increase in net loss compared to the previous year.
Read more →PGENPrecigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
Precigen is co-hosting the 2025 International RRP Awareness Day on June 11, 2025, alongside the Recurrent Respiratory Papillomatosis Foundation. The event aims to raise awareness about RRP, a chronic disease caused by HPV 6/11, which affects both children and adults. Despite the lack of FDA-approved treatments, the event will highlight the need for new therapies and support for affected individuals and their families.
Read more →PGENPrecigen Reports Full Year 2024 Financial Results and Business Updates
Precigen, Inc. reported its full year 2024 financial results, highlighting significant milestones for its PRGN-2012 therapy, including a BLA submission with priority review from the FDA. The company anticipates a potential launch in 2025, bolstered by a strengthened financial position. However, it also reported a net loss of $126.2 million and a 37% decrease in total revenues compared to the previous year.
Read more →PGENPrecigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
Precigen, Inc. has announced that it will release its full-year 2024 financial results and provide business updates on March 19, 2025. A conference call will be held at 4:30 PM ET to discuss these results. Participants are encouraged to join the call early to ensure timely connection. Precigen focuses on developing advanced gene and cell therapies.
Read more →PGENFDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced that the FDA has accepted the company's biologics license application for PRGN-2012, a gene therapy aimed at treating adults with recurrent respiratory papillomatosis (RRP). The therapy has been granted Priority Review, reducing the evaluation timeline to six months, with a target action date of August 27, 2025. If approved, PRGN-2012 will be the first FDA-approved therapy for RRP, a condition currently managed via repeated surgeries that address symptoms but not causes. The pivotal clinical study indicated significant efficacy, with many patients experiencing reduced surgical interventions post-treatment.
Read more →PGEN▼ -8.9%on this news
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference – PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA ...
Precigen, Inc. is set to present its plans for PRGN-2012, aimed at becoming the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP), at the 43rd Annual J.P. Morgan Healthcare Conference. The company has completed the Biologics License Application (BLA) submission and is actively working on commercial readiness with a robust cash position of approximately $100 million. The market potential for PRGN-2012 is significant, with an estimated 27,000 adult patients in the U.S. and plans to expand globally. The company is also pursuing further opportunities with its AdenoVerse platform in other HPV-related conditions.
Read more →PGENPrecigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 16, 2025. Helen Sabzevari, PhD, President and CEO, will discuss the company's innovative gene and cell therapies. The conference provides an important platform for Precigen to share developments and engage with investors. However, the company has cautioned that forward-looking statements involve risks that may affect actual outcomes.
Read more →PGEN▲ +28.5%on this news· ran to +65% by day 3
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis – PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatment of adults with RRP, a rare and devastating chronic disease...
Precigen, Inc. has successfully completed the submission of a biologics license application (BLA) to the FDA for its investigational gene therapy, PRGN-2012, aimed at treating adults with recurrent respiratory papillomatosis (RRP). This therapy, which has received Breakthrough Therapy Designation, may become the first approved treatment for RRP, a chronic disease currently managed only through repeated surgeries. The BLA is supported by clinical data demonstrating promising safety and efficacy outcomes from a pivotal study, including significant patient responses. The company is now awaiting the FDA's decision on the acceptance of the BLA and the setting of a review timeline.
Read more →PGENPrecigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. has announced a private placement offering of its 8.00% Series A Convertible Perpetual Preferred Stock, expected to raise $79 million. The funds will be used for working capital and general corporate purposes, extending the company's cash runway into 2026. The offering, led by Patient Capital Management, includes warrants for common stock purchase.
Read more →PGENPrecigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock GERMANTOWN, Md.
Precigen, Inc. has announced a private placement offering of its 8.00% Series A Convertible Perpetual Preferred Stock, expecting to raise $79 million before expenses. With this financing, the company aims to extend its cash runway into 2026, supporting its upcoming PRGN-2012 commercial launch planned for the second half of 2025, pending regulatory approval. The private placement involves high-profile investors and is subject to customary closing conditions and shareholder approvals.
Read more →PGENPrecigen Reports Third Quarter 2024 Financial Results and Business Updates - Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA su
Precigen, Inc. announced its third quarter 2024 financial results, highlighting a pre-BLA meeting with the FDA that confirmed alignment on the Biologics License Application (BLA) for PRGN-2012 in RRP. The company is focusing resources on advancing PRGN-2012, with plans for a rolling BLA submission in Q4 2024, while also preparing for a potential 2025 product launch. Financial results show increased costs in certain areas, including SG&A and R&D, as well as a 31% drop in revenues compared to the prior year. Additionally, preclinical data for the UltraCAR-T platform indicates promising advancements in cancer treatment.
Read more →PGEN▼ -5%on this news· ran to -18% by day 3shared move
Precigen to Participate in the Stifel 2024 Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. (Nasdaq: PGEN) announced that its President and CEO, Helen Sabzevari, PhD, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on November 19, 2024. This event underscores Precigen's commitment to advancing its innovative gene and cell therapies. The conference will take place in New York from November 18 to 19, 2024. Details of the event can be accessed on the company's website. Precigen emphasizes that forward-looking statements regarding its business development are subject to risks and uncertainties.
Read more →PGENPrecigen to Participate in the 2024 Cantor Global Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. (Nasdaq: PGEN) announced its participation in the 2024 Cantor Global Healthcare Conference, with CEO Helen Sabzevari set to engage in a fireside chat on September 18, 2024. The event will run from September 17 to 19, 2024, in New York and aims to improve visibility for the company's innovative gene and cell therapies. Investors can find further details on the company's website. However, management also issued a caution regarding forward-looking statements tied to their expectations and projections related to ongoing developments.
Read more →PGENPrecigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates - In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meetin
Precigen reported its second quarter and first half 2024 financial results, highlighting significant advancements in its PRGN-2012 gene therapy program. The company announced promising pivotal study results at the ASCO annual meeting, where over half of RRP patients achieved Complete Response. With the recent appointment of a Chief Commercial Officer and a strategic focus on the PRGN-2012 program, Precigen is gearing up for a rolling BLA submission in late 2024. However, the company faces challenges such as substantial impairment charges from its ActoBio subsidiary and increasing operational costs, affecting its net financial performance.
Read more →PGEN▼ -13.4%on this newsshared move
Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced that it will release its second quarter and first half 2024 financial results on August 14, 2024. The company will also host a conference call to discuss these results and provide a general business update. Stakeholders are encouraged to participate in the call by dialing in ahead of time. The announcement includes a cautionary statement regarding forward-looking statements, indicating that actual results may vary from the company's expectations.
Read more →PGEN▼ -12.6%on this newsshared move
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 35,294,118 shares of its common stock at a public...
Precigen, Inc. announced the pricing of a public offering of 35,294,118 shares at $0.85 per share, expected to generate approximately $30 million before expenses. The offering is set to close on August 9, 2024, subject to customary closing conditions. Precigen intends to utilize the net proceeds primarily for advancing its lead product, PRGN-2012, towards regulatory approval and for general corporate purposes, aiming to extend its operational funding into early 2025. Stifel is acting as the sole book-running manager for this offering.
Read more →PGENPrecigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch - PRG-2012 is on track for a rolling BLA submission under an accelerated approval pathway; patient enrollment initiated in the
Precigen, Inc. has announced a strategic reprioritization of its clinical portfolio, focusing on the PRGN-2012 gene therapy. This therapy aims to treat recurrent respiratory papillomatosis (RRP) and is on track for a rolling submission of a biologics license application (BLA) under an accelerated approval pathway, expected in the second half of 2024. Though the company has initiated patient enrollment in a confirmatory clinical trial, it is also streamlining resources, resulting in a workforce reduction of over 20%. This strategy is intended to enhance readiness for potential commercialization in 2025.
Read more →PGENPrecigen Announces Proposed $30 Million Public Offering of Common Stock Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced a $30.0 million underwritten public offering of its common stock. In addition,...
Precigen, Inc. has announced a proposed underwritten public offering of $30 million of its common stock, with an option for underwriters to purchase an additional $4.5 million. The offering is subject to market conditions and various other factors. The final terms of the offering will be disclosed in a subsequent prospectus supplement. Precigen also cautioned that there are risks involved that may affect the completion of the offering as planned.
Read more →PGENPrecigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. has strategically reprioritized its clinical portfolio to focus on the potential commercialization of PRGN-2012, a gene therapy for recurrent respiratory papillomatosis. The company plans to submit a rolling BLA under an accelerated approval pathway by the end of 2024. As part of this strategy, Precigen has reduced its workforce and paused several clinical and preclinical programs.
Read more →PGENPrecigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced the appointment of Phil Tennant as Chief Commercial Officer to lead commercial strategy for its potential gene therapy PRGN-2012, aimed at treating recurrent respiratory papillomatosis. Tennant brings over 30 years of experience in the biotech industry, having previously worked with prominent companies like Bristol Myers Squibb and Astellas Pharma. His role will focus on enhancing the company's readiness for a potential product launch, emphasizing the need for non-surgical treatment options for patients. The company is optimistic about the therapeutic potential of PRGN-2012 while acknowledging inherent risks in development.
Read more →PGEN▲ +11.4%on this news· ran to +22% by day 3
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response – Phase 1/2 pivotal study met the primary safety and efficacy endpoints – – 51% (18 out of 35) of patients achieved Complete Response, requiring no...
Precigen, Inc. announced positive results from its Phase 1/2 pivotal study of PRGN-2012 in patients with recurrent respiratory papillomatosis (RRP). The trial demonstrated that 51% of the 35 patients achieved Complete Response, eliminating the need for surgeries. Additionally, 86% of patients experienced a significant reduction in surgical interventions following treatment. The investigational gene therapy was well-tolerated, showing no serious adverse events. Precigen plans to submit a rolling Biologics License Application for PRGN-2012 by the end of 2024.
Read more →PGENPrecigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced a webcast to be held on June 3, 2024, where they will detail pivotal study results for PRGN-2012, aimed at treating recurrent respiratory papillomatosis. The results will be presented during the ASCO Annual Meeting by a notable lead investigator. This significant update marks a potential breakthrough in the treatment landscape for this condition, further underlined by CDC recognitions, including Orphan Drug and Breakthrough Therapy Designations.
Read more →PGENPrecigen Reports First Quarter 2024 Financial Results and Business Updates - Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASC
Precigen reported its first quarter 2024 financial results and outlined business updates, highlighting the upcoming presentation of pivotal Phase 2 study data for PRGN-2012 at the 2024 ASCO Annual Meeting. Preparations for a rolling BLA submission expected in late 2024 are underway, as the company aims for a potential launch in 2025. Additionally, ongoing clinical trials for PRGN-2009 and collaboration with the Recurrent Respiratory Papillomatosis Foundation to raise awareness are also noted. Financially, Precigen has $44.8 million in cash and is assessing further financing opportunities to support its growth.
Read more →PGENPrecigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. has announced that it will report its first quarter 2024 financial results on May 14, 2024, followed by a conference call on June 3, 2024. The call will focus on the pivotal Phase 2 study of PRGN-2012 for treating recurrent respiratory papillomatosis, which will be presented at the 2024 ASCO Annual Meeting. No additional details about the conference call have been provided yet. Precigen aims to shed light on its progress and developments in gene and cell therapies.
Read more →PGENPrecigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced that clinical data from its pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy will be presented at the 2024 ASCO Annual Meeting. This study indicates the treatment's effectiveness in achieving complete and durable responses for patients with recurrent respiratory papillomatosis (RRP). The presentation will occur on June 3, 2024, highlighting the company’s innovative approach to gene and cell therapies. PRGN-2012 has received several designations from regulatory bodies, underscoring its promise in the treatment landscape for RRP.
Read more →PGENPrecigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. has partnered with the Recurrent Respiratory Papillomatosis Foundation to host the inaugural International RRP Awareness Day on June 11, 2024. This event aims to raise awareness of recurrent respiratory papillomatosis (RRP), a rare disease with no FDA-approved therapies. Activities will include a panel discussion featuring RRP patients, caregivers, and healthcare professionals. The initiative focuses on building community connections and improving the dialogue among stakeholders in the RRP space.
Read more →PGENPrecigen Reports Full Year 2023 Financial Results and Business Updates - Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA und
Precigen, Inc. has reported its full year 2023 financial results, highlighting its strategies and advancements in immunotherapy, particularly PRGN-2012 and UltraCAR-T therapies. The company is set to present pivotal Phase 2 data and plans to submit a Biologics License Application (BLA) for PRGN-2012 within the year, with expectations for a 2025 launch. While there are positive developments, the company faces challenges such as decreased revenues and ongoing losses, coupled with an impairment charge on one of its subsidiaries.
Read more →PGENPrecigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced a virtual fireside chat hosted by Cantor Fitzgerald to discuss its investigational PRGN-2012 AdenoVerse immunotherapy targeting recurrent respiratory papillomatosis. The event will feature key members from Precigen and the NIH, highlighting the unique aspects of the therapy, including its gorilla adenovector technology. PRGN-2012 is currently being studied in a Phase 1/2 trial and has received notable designations from regulatory authorities to expedite its development. Additional details about the event are available on Precigen's investor relations website.
Read more →PGENPrecigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced that it will report its fourth quarter and full year 2023 financial results on March 19, 2024. A conference call will occur on the same day to discuss these results and provide a business update. The company is known for developing innovative gene and cell therapies, including CAR-T and AdenoVerse therapies. Forward-looking statements in the release caution that actual future results may differ significantly from the company's expectations.
Read more →PGENPrecigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. has announced its participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, scheduled for February 13 and 14, 2024. CEO Helen Sabzevari will lead the presentation on February 13, highlighting the company's advancements in gene and cell therapies. Interested parties can access details of the event through Precigen's official website. The announcement showcases Precigen's strategic engagement in the healthcare sector, aiming to showcase its therapeutic innovations.
Read more →PGENPrecigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. has been granted Orphan Drug Designation by the European Commission for its investigational therapy PRGN-2012, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by human papillomavirus. This designation follows prior recognition from the FDA in the United States and underscores the company's commitment to developing innovative therapies for patients with limited treatment options. PRGN-2012, which utilizes gorilla adenovector technology, aims to elicit targeted immune responses and has demonstrated promising results in preventing surgical interventions for RRP. The company is preparing for further studies and potential commercialization in the coming years.
Read more →PGEN▲ +8.5%on this news
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. is set to present pipeline updates at the 42nd Annual J.P. Morgan Healthcare Conference. Key highlights include anticipated Phase 2 data for PRGN-2012 in recurrent respiratory papillomatosis (RRP) and plans for a Biologics License Application (BLA) submission in late 2024. The company is preparing for a potential commercial launch in 2025. Additionally, updates on UltraCAR-T therapies and other investigational products will be shared.
Read more →PGEN▲ +8.5%on this news
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference - PRGN-2012 Phase 2 pivotal study data in RRP is anticipated in the second quarter of 2024; the Company plans to s
Precigen, Inc. has highlighted recent updates to its pipeline ahead of the 42nd Annual J.P. Morgan Healthcare Conference, scheduled for January 10, 2024. The company anticipates presenting data from its Phase 2 pivotal study of PRGN-2012 for recurrent respiratory papillomatosis (RRP) in the second quarter of 2024. Precigen is also focusing on its UltraCAR-T therapies and has received breakthrough therapy designation for RRP treatment, signaling strong potential for commercialization. However, the company acknowledges that its forward-looking statements are subject to risks and uncertainties.
Read more →PGEN▼ -5.7%on this news
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Helen Sabzevari, the company's President and CEO, is set to deliver a corporate and clinical overview at the event. This appearance highlights Precigen's focus on innovative gene and cell therapies aimed at enhancing patient lives. Further event details are available on the company's website, inviting investor interest and engagement.
Read more →PGENPrecigen to Participate in the JMP Securities Hematology and Oncology Summit Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. has announced that its President and CEO, Dr. Helen Sabzevari, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit scheduled for December 6, 2023. The event will showcase Precigen's focus on innovative gene and cell therapies. Participants will find details on this event on Precigen's official website. The press release also includes cautionary statements regarding forward-looking claims made by the company, acknowledging potential risks and uncertainties.
Read more →PGENPrecigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs - Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal
Precigen, Inc. reported its third quarter 2023 financial results and updates on its clinical programs, highlighting significant advancements in its lead therapy, PRGN-2012. Following the FDA's guidance in August 2023, the ongoing PRGN-2012 study will facilitate a pivotal approval request. The company has made progress in reducing operating costs and plans to submit a Biologics License Application (BLA). However, financial results showed a notable decline in revenues and continued operational losses compared to the previous year.
Read more →PGEN▲ +12.9%on this newsshared move
Precigen to Participate in the Stifel 2023 Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. (Nasdaq: PGEN) announced that its President and CEO, Dr. Helen Sabzevari, will present a company overview at the Stifel 2023 Healthcare Conference on November 15, 2023. The event will focus on Precigen's innovative gene and cell therapies, particularly its CAR-T and AdenoVerse technologies. Interested participants can access details on the company's website. The company advises that its forward-looking statements are subject to various risks and uncertainties which may affect actual outcomes.
Read more →PGEN▼ -8.3%on this news
Precigen to Participate in Upcoming Leading Investor and Industry Conferences Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced the upcoming participation of its President and CEO, Helen Sabzevari, in notable investor and industry conferences. The engagements include the Cantor Global Healthcare Conference and the Cell & Gene Meeting on the Mesa, among others. These events are aimed at discussing advancements in gene and cell therapies, including the company's focus on CAR-T and AdenoVerse therapies. The press release also cautions about forward-looking statements regarding the company's business plans and potential risks involved.
Read more →PGEN▲ +6.9%on this news· ran to +43% by day 3
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval – FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be...
Precigen, Inc. announced that the FDA has validated the ongoing Phase 1/2 study of its PRGN-2012 AdenoVerse immunotherapy as pivotal for filing an accelerated biologics license application (BLA). The FDA confirmed that no further randomized controlled trials are necessary, and the primary endpoints for efficacy and safety have been agreed upon. This breakthrough could potentially make PRGN-2012 the first treatment for recurrent respiratory papillomatosis (RRP), a condition currently managed through repeated surgeries. The study has completed enrollment and dosing in its Phase 2 portion, with results expected by mid-2024.
Read more →PGEN▲ +6.9%on this news· ran to +43% by day 3
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 – The FDA confirmed that the ongoing Phase 1/2 single arm study of PRGN-2012 in RRP will serve as the pivotal study to support accelerated approval...
Precigen, Inc. reported its second quarter and first half 2023 financial results, highlighting that the FDA confirmed the ongoing Phase 1/2 study of PRGN-2012 will serve as the pivotal study for accelerated approval. The company is prioritizing its portfolio to enhance the success of this program while extending its cash runway into 2025 through cost-saving measures. Despite these advancements, the company faced a notable decrease in revenues and continues to report significant operational losses.
Read more →PGEN▲ +6.9%on this news· ran to +43% by day 3
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 - The FDA confirmed that t
Precigen, Inc. reported its financial results for the second quarter and first half of 2023, highlighting a key FDA milestone for its PRGN-2012 therapy. The FDA confirmed that PRGN-2012's ongoing Phase 1/2 study will serve as the pivotal study for accelerated approval, which is a significant step towards commercialization. The company also emphasized its focus on capital allocation to ensure a projected cash runway extending into 2025. Further financial updates revealed a reduction in operational losses compared to the prior year, signaling improved fiscal health.
Read more →PGEN▼ -6.7%on this news
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. will announce its second quarter and first half 2023 financial results on August 9, 2023. The biopharmaceutical company specializes in gene and cell therapies. Following the release, a conference call is scheduled for 8:30 AM ET to discuss the results and provide a business update. The event aims to enhance investor relations and share insights into the company's objectives and developments.
Read more →PGENPrecigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced that the FDA has granted Breakthrough Therapy Designation for its investigational PRGN-2012 AdenoVerse immunotherapy, aimed at treating recurrent respiratory papillomatosis (RRP). This designation is based on promising Phase 1 clinical data that showed half of the patients treated were surgery-free after 12 months. With no approved therapeutic options currently available for RRP, this development is seen as a significant advancement in the management of the disease. The company plans to engage with the FDA to expedite the development and potential approval process for PRGN-2012.
Read more →PGENPrecigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients – PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity – – PRGN-3005 cells demonstrated...
Precigen, Inc. has reported positive Phase 1 data for its PRGN-3005 UltraCAR-T cells in the treatment of advanced stage platinum resistant ovarian cancer. The data, presented at the 2023 ASCO Annual Meeting, demonstrated a favorable safety profile, with no dose limiting toxicities and encouraging anti-tumor activity, as 67% of patients showed decreased tumor burden following intravenous infusion after lymphodepletion. The ongoing Phase 1b study aims to further evaluate the efficacy of the treatment, which employs an innovative overnight manufacturing process for the UltraCAR-T cells.
Read more →PGENPrecigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers – PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers...
Precigen, Inc. reported positive Phase 1 results for PRGN-2009, an off-the-shelf immunotherapy for recurrent/metastatic HPV-associated cancers. The treatment, both as a monotherapy and in combination with an investigational checkpoint inhibitor, showed a 30% overall response rate in heavily pre-treated patients. The safety profile was favorable, with only mild treatment-related adverse events observed. Precigen plans to advance to Phase 2 studies to further assess the efficacy of PRGN-2009 in combination with a checkpoint inhibitor.
Read more →PGENPrecigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer – HPV is responsible for more than 90 percent of cervical cancer cases globally with approximately 300,000 women living with cervical cancer in the...
Precigen, Inc. has received FDA clearance for its Investigational New Drug application to initiate a Phase 2 study of its PRGN-2009 Off-the-Shelf AdenoVerse immunotherapy in combination with pembrolizumab for patients with recurrent or metastatic cervical cancer. The study will assess the efficacy and safety of the combination therapy compared to pembrolizumab alone in patients previously treated with pembrolizumab. The decision follows promising results from Phase 1 data, which indicated a favorable safety profile and a 30% objective response rate in heavily pre-treated patients. The Phase 2 study aims to further evaluate the treatment's potential in addressing the needs of this patient population.
Read more →PGENPrecigen Reports First Quarter 2023 Financial Results and Business Updates - Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse immunotherapy in RRP demonstrated favorable safety profile and significant re
Precigen reported positive developments in its Q1 2023 financial results, particularly highlighting favorable Phase 1 clinical data for the PRGN-2012 AdenoVerse immunotherapy, which indicates a significant reduction in surgeries needed for patients. The company completed enrollment in a Phase 2 study for the same therapy and dosed the first patient in its Phase 1/1b study of PRGN-3007. Additionally, Precigen enhanced its financial resources by raising $72.8 million and regaining exclusive rights to key CAR-T targets, CD19 and BCMA. These advancements position Precigen favorably within the competitive landscape of gene and cell therapies.
Read more →PGEN▲ +8.8%on this news
Precigen to Announce First Quarter 2023 Financial Results on May 10th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. (Nasdaq: PGEN) has announced it will release its first quarter 2023 financial results on May 10, 2023. A conference call will follow at 8:00 AM ET to discuss these results and provide a general business update. The company, which focuses on gene and cell therapies, has also issued a cautionary statement about forward-looking projections due to potential risks, including impacts from the COVID-19 pandemic.
Read more →PGENPrecigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced the presentation of clinical data for its PRGN-3005 UltraCAR-T and PRGN-2009 AdenoVerse immunotherapy at the upcoming 2023 ASCO Annual Meeting. The Phase 1 dose escalation study of PRGN-3005 targets advanced, recurrent platinum-resistant ovarian cancer, while PRGN-2009 is evaluated in HPV-associated cancers. The UltraCAR-T technology offers a novel means for therapy with an overnight manufacturing process, potentially enhancing patient treatment timelines. This announcement highlights the company's commitment to innovative therapies in oncology.
Read more →PGEN▲ +10.5%on this news
Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023 – First preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR) – ...
Precigen has presented exciting preclinical data for its next-generation UltraCAR-T platform targeting mesothelin (MSLN) at the AACR Annual Meeting 2023. The study highlights the engineered CAR-T cells' unique intrinsic PD-1 blockade, which aims to improve safety and efficacy in treating cancers such as mesothelioma and ovarian cancer. Results showed significant tumor reduction and cell persistence upon rechallenge, demonstrating the potential for long-lasting antitumor responses. This data marks a significant advancement in Precigen's efforts to innovate personalized cell therapies for cancer treatment.
Read more →PGEN▲ +5.7%on this news
Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. has amended its exclusive license agreement with Alaunos Therapeutics to regain exclusive rights to the CAR-T targets CD19 and BCMA, allowing for unhindered development of its UltraCAR-T therapies. This strategic shift is aimed at improving cost-effective treatment options for cancer patients while eliminating future royalty payments. The move positions Precigen to accelerate its ongoing clinical programs across various cancer indications, leveraging the UltraCAR-T platform and adding interleukin (IL)-12 gene therapy capabilities.
Read more →PGEN▲ +15.4%on this news· ran to +27% by day 3shared move
Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. has announced the successful dosing of the first patient in a Phase 1/1b clinical trial for PRGN-3007, a next-generation UltraCAR-T therapy. This investigational treatment aims to address advanced ROR1-positive hematological and solid tumors, potentially enhancing the safety profile with its intrinsic PD-1 inhibition mechanism. The trial, which commenced following the patient's dosing, involves a decentralized manufacturing process designed to bring this novel therapy to patients within one day after gene transfer. Precigen’s innovative approach to CAR-T therapy may provide significant benefits over existing treatment options.
Read more →PGENPrecigen to Participate in a Virtual Fireside Chat at Cantor's The Future of Oncology Virtual Symposium Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. announced that its President and CEO, Helen Sabzevari, will participate in a virtual fireside chat at Cantor's 'The Future of Oncology' Virtual Symposium on April 4, 2023. This event aims to showcase innovative advancements in oncology. Precigen specializes in gene and cell therapies, and this participation may enhance the company's visibility in the biopharmaceutical sector.
Read more →PGENPrecigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates - Achieved significant clinical progress for UltraCAR-T and AdenoVerse investigational therapeutics in 2022 - - Presented positive
Precigen, Inc. has reported its fourth quarter and full year 2022 financial results, showcasing notable advancements in its UltraCAR-T and AdenoVerse clinical programs. The company achieved encouraging safety and efficacy outcomes from ongoing Phase 1 trials, which position it for a promising year ahead in 2023. Despite a decrease in total revenues and significant losses from operations, Precigen has improved its financial standing through strategic maneuvers such as the divestiture of Trans Ova Genetics and a public stock offering. These actions are expected to provide a solid cash runway to support ongoing clinical projects.
Read more →PGENPrecigen Announces Closing of Public Offering of Common Stock Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold...
Precigen, Inc. has successfully closed its underwritten public offering of common stock, selling 42,857,143 shares at a price of $1.75 each. This offering generated gross proceeds of approximately $75 million before deductions. The offering was conducted under a previously filed shelf registration statement and involved notable financial institutions such as J.P. Morgan Securities LLC and Cantor Fitzgerald & Co. A final prospectus supplement related to the offering has been filed with the SEC and is accessible through their website.
Read more →PGENPrecigen Announces Proposed $75.0 Million Public Offering of Common Stock Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its common stock. In addition,...
Precigen, Inc. has announced a proposed public offering of $75 million worth of its common stock. The company is also granting underwriters a 30-day option to purchase an additional $11.25 million of stock. Market conditions will significantly influence the completion and terms of this offering, which underscores inherent uncertainties. The offering will proceed under an effective registration statement previously filed with the SEC.
Read more →PGENPrecigen Announces Pricing of $75.0 Million Public Offering of Common Stock Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public...
Precigen, Inc. has priced an underwritten public offering of 42,857,143 shares of its common stock at $1.75 per share, potentially raising around $75 million. The offering, expected to close on January 27, 2023, aims to fund the development of both clinical and preclinical product candidates. J.P. Morgan Securities LLC leads the offering, with other firms participating as managers. Although the offering is contingent on market conditions and customary closing criteria, it represents a significant financial boost for Precigen.
Read more →PGENPrecigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis - Repeated administ
Precigen Inc. reported positive results from its Phase 1 trial of PRGN-2012, an off-the-shelf immunotherapy for recurrent respiratory papillomatosis (RRP). The data shows that 50% of patients achieved a complete response, remaining surgery-free for at least 12 months post-treatment, which is significant compared to previous surgery frequencies. The treatment was well-tolerated, exhibiting no serious adverse events, and provided a considerable reduction in surgical requirements. Precigen plans to further discuss its regulatory strategy with the FDA as it progresses.
Read more →PGEN▲ +8.6%on this news· ran to +30% by day 3
Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference - Company achieved significant progress for its clinical pipeline in 2022 - - Precigen to host R&D Day virtual event o
Precigen, Inc. presented updates on its clinical pipeline at the 41st Annual J.P. Morgan Healthcare Conference, highlighting significant progress made in 2022. The company plans to host an R&D Day on January 24, 2023, to discuss safety and efficacy data from its PRGN-2012 AdenoVerse immunotherapy in recurrent respiratory papillomatosis. Precigen aims to continue advancing its clinical programs in 2023, focusing on therapies that address critical patient needs and leveraging its innovative UltraCAR-T and AdenoVerse platforms.
Read more →PGEN▲ +5.4%on this news
Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
Precigen, Inc. will host a virtual R&D event on January 24, 2023, to present safety and efficacy data from the Phase 1 trials of its PRGN-2012 AdenoVerse Immunotherapy aimed at treating recurrent respiratory papillomatosis (RRP). The event will feature key presentations from leading investigators, including Clint T. Allen and Precigen's President, Helen Sabzevari. This follows promising advancements in the study, signaling potential benefits for an underserved patient population. Participants will be able to access a live webcast, with an archived version available post-event.
Read more →PGEN▼ -5.7%on this news
Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Dec. 19, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen
Read more →PGENPrecigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients – Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – –...
– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – – PRGN-3006 infusion with lymphodepletion resulted in a decrease in bone marrow blasts in 60% of heavily pre-treated patients – – Singl
Read more →PGEN▼ -8.1%on this news
Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs - Company will host virtual R&D event in early January 2023, timed to coincide with the 41 st Annual JP Morgan Healthcare Conference
Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase complete clinical trial data from Phase 1 dose
Read more →PGENPrecigen to Announce Third Quarter 2022 Financial Results on November 9th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Nov. 2, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release third quarter 2022 financial
Read more →PGEN▼ -13.8%on this news
Precigen Names Rutul R. Shah Chief Operating Officer GERMANTOWN, MD
Rutul R. Shah Chief Operating Officer September 21, 2022 - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Rutul R. Shah as the Company's Chief Operat
Read more →PGENPrecigen to Participate in the 2022 Wells Fargo Healthcare Conference Precigen, Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Sept. 1, 2022 /PRNewswire/ -- Precigen, Inc. (NASDAQ: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari , PhD, President and CEO of Pre
Read more →PGENPrecigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics
Precigen Completes Sale of Non-Healthcare Subsidiary Proceeds include $170 million in upfront cash and up to $10 million earn-out over two years - Md., Aug. 22, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of i
Read more →PGENPrecigen Reports Second Quarter and First Half 2022 Financial Results - Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; M
Precigen Reports Second Quarter and First Half 2022 Financial Results GERMANTOWN, MD, August 8, 2022 - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today anno
Read more →PGENPrecigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Aug. 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first hal
Read more →PGEN▲ +14.9%on this news
Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics Divestiture of this non-healthcare subsidiary will largely complete Precigen's strategy to focus exclusively on healthcare - GERMANTOWN, Md., July 5, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a bi
Read more →PGENPrecigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , June 27, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari , PhD, President and CEO of Pre
Read more →PGENPrecigen to Participate in the 2022 H.C. Wainwright Global Investment Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , May 17, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari , PhD, President and CEO of Prec
Read more →PGEN▼ -8%on this news
Precigen Reports First Quarter 2022 Financial Results and Business Updates - Fast Track designation received for PRGN-3006 UltraCAR-T , an important milestone for patients with relapsed or refractory acute myeloid leukem
Precigen Reports First Quarter 2022 Financial Results and Business Updates Fast Track designation received for PRGN-3006 UltraCAR-T , an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly progressing disease with limited treatment op
Read more →PGEN▲ +11.5%on this news
Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
– Acute myeloid leukemia (AML) is among the most common types of leukemia in adults – – PRGN-3006 UltraCAR-T previously received orphan drug designation (ODD) in patients with AML by the US Food and Drug Administration (FDA) – – PRGN-3006 UltraCAR-T has demonstrated a favorable
Read more →PGENPrecigen Reports Fourth Quarter and Full Year 2021 Financial Results - 2021 clinical milestone objectives successfully accomplished - - Positive clinical data presented across three platforms - UltraCAR-T , AdenoVerse TM
Precigen Reports Fourth Quarter and Full Year 2021 Financial Results - 2021 clinical milestone objectives successfully clinical data presented across three platforms - UltraCAR-T , AdenoVerseTM, ActoBioticsTM - and five clinical programs - offering to strengthen balance shee
Read more →PGENPrecigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Jan. 12, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 40th Annual J.
Read more →PGEN▼ -10.5%on this news
Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Jan. 5, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari , PhD, President and CEO of Prec
Read more →PGENPrecigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,...
GERMANTOWN, Md. , Dec. 13, 2021 /PRNewswire/ -- Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive interim data at the 63rd ASH Annual Meeting and Exposition
Read more →PGEN▼ -10.7%on this news
Precigen to Present at the Stifel 2021 Virtual Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Nov. 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari , PhD, President and CEO of Pre
Read more →PGENPrecigen Achieves Significant Clinical Progress for UltraCAR-T and AdenoVerse Therapies - 50% (3 out of 6) objective response rate (ORR) in relapsed or refractory (r/r) acute myeloid leukemia (AML) patients treated with
Precigen Achieves Significant Clinical Progress for UltraCAR-T and AdenoVerse Therapies 50% (3 out of 6) objective response rate (ORR) in relapsed or refractory (r/r) acute myeloid leukemia (AML) patients treated with PRGN-3006 at the two lowest dose levels (a single administr
Read more →PGENPrecigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Oct. 27, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a virtual event on Thursd
Read more →PGENPrecigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md., Oct. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cl
Read more →PGENPrecigen Appoints Harry Thomasian Jr. as Chief Financial Officer GERMANTOWN, MD
Harry Thomasian Jr. as Chief Financial Officer October 12, 2021 - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Harry Thomasia
Read more →PGENPrecigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Sept. 1, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen
Read more →PGENPrecigen Reports Second Quarter and First Half 2021 Financial Results - Company to provide comprehensive clinical pipeline and data updates at R&D call on November 4 th - GERMANTOWN, MD
Precigen Reports Second Quarter and First Half 2021 Financial Results GERMANTOWN, MD, August 9, 2021 - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today anno
Read more →PGENPrecigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first hal
Read more →PGENPrecigen to Present at the JMP Securities Life Sciences Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md ,, June 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen
Read more →PGENPrecigen Reports First Quarter 2021 Financial Results - Company on track to achieve stated 2021 milestones - - Initiated Phase 2 clinical trial of PRGN-2009 AdenoVerse immunotherapy - - Initiated Phase 1 clinical trial o
Precigen Reports First Quarter 2021 Financial on track to achieve stated 2021 milestones - Phase 2 clinical trial of PRGN-2009 AdenoVerse immunotherapy - Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosi
Read more →PGENPrecigen Announces Departure of Chief Financial Officer - Commences search for new CFO - Germantown, Maryland
Precigen Announces Departure of Chief Financial - Commences search for new CFO - Germantown, Maryland, March 30, 2021 - Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today an
Read more →PGENPrecigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,...
GERMANTOWN, Md. , March 23, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the Phase I study of PRGN-
Read more →PGENPrecigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,...
GERMANTOWN, Md. , March 18, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan d
Read more →PGENPrecigen Reports Fourth Quarter and Full Year 2020 Financial Results Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic Strengthened balance sheet with s
Precigen Reports Fourth Quarter and Full Year 2020 Financial Results Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic Strengthened balance sheet with successful public offering while streamlining operations an
Read more →PGENPrecigen to Announce Fourth Quarter and Full Year 2020 Financial Results on March 1st Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Feb. 22, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release fourth quarter and full yea
Read more →PGENPrecigen to Participate in Guggenheim Healthcare Talks Oncology Day Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Feb. 4, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen,
Read more →PGENPrecigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold...
GERMANTOWN, Md. , Jan. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 17,250,000 shares of its common stock at a public offering price of $7.50 per share,
Read more →PGENPrecigen Announces Pricing of $112.5 Million Public Offering of Common Stock Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public...
GERMANTOWN, Md. , Jan. 22, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-da
Read more →PGENPrecigen Announces Proposed Public Offering of Common Stock Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of shares of its common stock. In addition, Precigen...
GERMANTOWN, Md. , Jan. 21, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ) today announced it has commenced an underwritten public offering of shares of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase additional shares of
Read more →PGENForward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forwar
39th Annual J.P. Morgan Healthcare Conference 13 January 2021 Helen Sabzevari, PhD President & CEO EXHIBIT 99.1 Forward-looking Statements Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private
Read more →PGENPrecigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Jan. 13, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented clinical and preclinical updates at the 39th Annual
Read more →PGENPrecigen to Present at the 39th Annual J.P. Morgan Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Jan. 6, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen,
Read more →PGENPrecigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Jan. 5, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cl
Read more →PGENPrecigen Provides Latest Clinical Developments at Virtual R&D Update Event Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Dec. 15, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today held an R&D virtual event to provide an update on the latest p
Read more →PGENPrecigen to Host R&D Update Virtual Event on December 15th to Share Latest Clinical Developments Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Dec. 8, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a virtual event on Tuesday
Read more →PGENPrecigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T® at the 62nd ASH Annual Meeting and Exposition Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,...
GERMANTOWN, Md. , Dec. 7, 2020 /PRNewswire/ -- Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced at the 62nd ASH Annual Meeting and Exposition ( Abstract 2864 ) clin
Read more →PGENPrecigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator™ System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Nov. 16, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical implementation of its UltraPorator ™ system
Read more →PGENINTERNAL & CONFIDENTIAL Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results Company to provide comprehensive clinical pipeline and data updates in early December Continues to advance healthcare portfol
INTERNAL & CONFIDENTIAL Precigen Reports Third Quarter 2020 and Year-to-Date Company to provide comprehensive clinical pipeline and data updates in early December Continues to advance healthcare portfolio and improve fiscal performance by executing operational efficiencies Co
Read more →PGENPrecigen Reports Third Quarter 2020 and Year-to-Date Financial Results Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Nov. 9, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter and year-to-date financial results for
Read more →PGENPrecigen to Announce Third Quarter 2020 Financial Results on November 9th: Will host Pipeline and Data Update Call in Early December Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Nov. 2, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release third quarter 2020 financial results
Read more →PGENPrecigen Strengthens Focus on Strategic Partnerships and Names Gaurav Vij Head of Business Development Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Oct. 20, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Gaurav Vij as the Company's head of business development
Read more →PGENPrecigen's UltraPorator™ Receives FDA Clearance for Manufacturing UltraCAR-T® Cells in Clinical Trials Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Oct. 15, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced US Food and Drug Administration (FDA) clearance and
Read more →PGENPrecigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note GERMANTOWN, MD
Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of GERMANTOWN, MD, October 9, 2020 - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the l
Read more →PGENPrecigen to Present at H.C. Wainwright 22nd Annual Global Investment Conference Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Sept. 8, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen
Read more →PGENPrecigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-associated Cancers Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the...
GERMANTOWN, Md. , Aug. 17, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Preci
Read more →PGENPrecigen Reports Second Quarter and First Half 2020 Financial Results Announced proprietary electroporation device, UltraPorator , designed to scale-up UltraCAR-T manufacturing at multiple medical centers Announced posit
Precigen Reports Second Quarter and First Half 2020 Financial Results Announced proprietary electroporation device, UltraPorator , designed to scale-up UltraCAR-T manufacturing at multiple medical centers Announced positive topline results from Phase 1b study of AG019 ActoBioti
Read more →PGENEvent Name: Precigen Second Quarter 2020 Financial Results Conference Call Event Date: Monday
Event Name: Precigen Second Quarter 2020 Financial Results Conference Call Event Date: Monday, August 10, 2020, 4:30 PM Eastern Time Steven Harasym; Precigen, Inc.; Head of Investor Relations Helen Sabzevari; Precigen, Inc.; President and Chief Executive Officer Tom Samuelso
Read more →PGENPrecigen to Announce Second Quarter and First Half 2020 Financial Results on August 10th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Aug. 3, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release second quarter and first half 2020 fi
Read more →PGENPreclinical Data for PRGN-3005 UltraCAR-T® Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,...
GERMANTOWN, Md. , June 22, 2020 /PRNewswire/ -- Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced preclinical data for its innovative investigational PRGN-3005 Ultra
Read more →PGENPrecigen to Participate in Upcoming JMP Securities Hematology and Oncology Forum Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , June 11, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen
Read more →PGENNotice: Precigen Announces Date and Location Change for its 2020 Annual Meeting of Shareholders In light of the ongoing COVID-19 pandemic and taking into account guidance and protocols issued by public health and government authorities,...
GERMANTOWN, Md. , June 4, 2020 /PRNewswire/ -- In light of the ongoing COVID-19 pandemic and taking into account guidance and protocols issued by public health and government authorities, Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development
Read more →PGENPrecigen to Present Preclinical Data for PRGN-3005 UltraCAR-T™ at the AACR Virtual Annual Meeting II in June 2020 Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,...
GERMANTOWN, Md. , May 15, 2020 /PRNewswire/ -- Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced preclinical data for its innovative investigational PRGN-3005 UltraC
Read more →PGENMAY 06, 2020 / 8:15PM GMT, Q1 2020 Precigen Inc Earnings Call CORPORATE PARTICIPANTS Helen Sabzevari Precigen, Inc. - President & CEO Steven Harasym Precigen, Inc. - Head of Investor Relations Tom Samuelson Precigen, Inc
Call CORPORATE PARTICIPANTS Helen Sabzevari Precigen, Inc. - President & CEO Steven Harasym Precigen, Inc. - Head of Investor Relations Tom Samuelson Precigen, Inc. - Head of Financial Strategy CONFERENCE CALL PARTICIPANTS Jason Nicholas Butler JMP Securities LLC, Research Divis
Read more →PGENPrecigen Reports First Quarter 2020 Financial Results Achieves significant progress in streamlining healthcare operations and reducing operating costs Maintains guidance for clinical readouts in 2020 Completes reduction
Precigen Reports First Quarter 2020 Financial Results Achieves significant progress in streamlining healthcare operations and reducing operating costs Maintains guidance for clinical readouts in 2020 Completes reduction in force at MBP Titan to focus resources on healthcare R
Read more →PGENPrecigen to Announce First Quarter 2020 Financial Results on May 6th Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , April 29, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release first quarter 2020 financial result
Read more →PGENPrecigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , April 20, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has
Read more →PGENPrecigen Reports Fourth Quarter and Year End 2019 Financial Results Company completed series of transactions to support tighter focus on healthcare Quarterly GAAP revenues from continuing operations of $17.0 million and
Precigen Reports Fourth Quarter and Year End 2019 Financial Results Company completed series of transactions to support tighter focus on healthcare Quarterly GAAP revenues from continuing operations of $17.0 million and net loss attributable to Precigen of $169.2 million, of w
Read more →PGENPrecigen to Announce Fourth Quarter and Full Year 2019 Financial Results on March 2nd Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...
GERMANTOWN, Md. , Feb. 24, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release fourth quarter and full year 2019 fi
Read more →PGENPRECIGEN COMPLETES SERIES OF TRANSACTIONS TO SOLIDIFY HEALTHCARE FOCUS - Company on Track to Advance Next-Generation Gene & Cell Therapies - - Company Name Changes to Precigen from Intrexon and Ticker Symbol to Nasdaq: P
PRECIGEN COMPLETES SERIES OF TRANSACTIONS TO SOLIDIFY HEALTHCARE FOCUS - Company on Track to Advance Next-Generation Gene & Cell Therapies - - Company Name Changes to Precigen from Intrexon and Ticker Symbol to Nasdaq: PGEN - GERMANTOWN, Md., Feb. 3, 2020 Precigen, Inc. (Nasda
Read more →PGENPrecigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients with Acute Myeloid Leukemia (AML) Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of...
GERMANTOWN, Md. , Jan. 6, 2020 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan
Read more →PGENINTREXON TO ACHIEVE $175M CASH GOAL, APPOINTS HELEN SABZEVARI, PhD, AS NEW PRESIDENT AND CEO AND WILL CHANGE NAME TO PRECIGEN TO REFLECT HEALTHCARE FOCUS Concurrent asset and stock sales reduce Intrexon non-healthcare ex
INTREXON TO ACHIEVE $175M CASH GOAL, APPOINTS HELEN SABZEVARI, PhD, AS NEW PRESIDENT AND CEO AND WILL CHANGE NAME TO PRECIGEN TO REFLECT HEALTHCARE FOCUS Concurrent asset and stock sales reduce Intrexon non-healthcare expenditure and provide funding for the trajectory of Intrex
Read more →PGENForward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation (Nasdaq: XON). Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions
Precigen, Inc. Helen Sabzevari, PhD President & CEO 14 January 2020 38th Annual J.P. Morgan Healthcare Conference Exhibit 99.1 Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation (Nasdaq: XON). Some of the statements made in this presentation are
Read more →PGENIntrexon Reports Third Quarter 2019 Financial Results Tightened focus on healthcare and on track to meet yearend transactional and cash goals Quarterly GAAP revenues of $23.0 million and net loss attributable to Intrexon
Intrexon Reports Third Quarter 2019 Financial Results Tightened focus on healthcare and on track to meet yearend transactional and cash goals Quarterly GAAP revenues of $23.0 million and net loss attributable to Intrexon of $53.6 million including non-cash charges of $19.5 GER
Read more →PGENIntrexon Reports Second Quarter and First Half 2019 Financial Results Quarterly GAAP revenues of $36.0 million and net loss attributable to Intrexon of $38.8 million including non-cash charges of $8.0 million GERMANTOWN,
Intrexon Reports Second Quarter and First Half 2019 Financial Results Quarterly GAAP revenues of $36.0 million and net loss attributable to Intrexon of $38.8 million including non-cash charges of $8.0 million GERMANTOWN, MD, August 8, 2019 Intrexon Corporation (NASDAQ: XON), a
Read more →PGENPrecigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of...
GERMANTOWN, Md. , Aug. 5, 2019 /PRNewswire/ -- Precigen, Inc. , a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON ) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today annou
Read more →PGENPrecigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS) Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of...
GERMANTOWN, Md. , June 26, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON ) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today annou
Read more →PGENIntrexon Reports First Quarter 2019 Financial Results Quarterly GAAP revenues of $23.3 million and net loss attributable to Intrexon of $60.7 million including non-cash charges of $17.8 million Quarterly Adjusted EBITDA
Intrexon Reports First Quarter 2019 Financial Results Quarterly GAAP revenues of $23.3 million and net loss attributable to Intrexon of $60.7 million including non-cash charges of $17.8 million Quarterly Adjusted EBITDA of $(39.2) million GERMANTOWN, MD, May 9, 2019 Intrexon
Read more →PGENPrecigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a clinical stage biopharmaceutical company specializing in the...
GERMANTOWN, Md. , April 25, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON ) and a clinical stage biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patie
Read more →PGENIntrexon Reports 2018 Fourth Quarter and Year End Financial Results Quarterly GAAP revenues of $43.2 million and net loss attributable to Intrexon of $340.5 million including non-cash charges of $311.0 million Previously
Intrexon Reports 2018 Fourth Quarter and Year End Financial Results Quarterly GAAP revenues of $43.2 million and net loss attributable to Intrexon of $340.5 million including non-cash charges of $311.0 million Previously Announced Reacquisition of Oncology Rights Drives $280M
Read more →PGENPrecigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of...
GERMANTOWN, Md. , Feb. 11, 2019 /PRNewswire/ -- Precigen, Inc. , a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON ) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today anno
Read more →PGENPrecigen Company Update Helen Sabzevari, PhD President, Precigen 7 January 2019 Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation (Nasdaq: XON). Some of the statements made in this present
Precigen Company Update Helen Sabzevari, PhD President, Precigen 7 January 2019 Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation (Nasdaq: XON). Some of the statements made in this presentation are forward-looking statements that involve a number
Read more →PGENPrecigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of...
GERMANTOWN, Md. , Dec. 31, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON ) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today annou
Read more →PGENForward-looking statements Today's business updates Introduction to Precigen's near-term R&D strategies Precigen's transformation to an agile R&D engine Agreement overviews for Ziopharm and Merck KGaA Introduction to Pre
Precigen Business Update Helen Sabzevari, PhD President, Precigen 26 December 2018 Exhibit 99.1 Forward-looking statements Today's business updates Introduction to Precigen's near-term R&D strategies Precigen's transformation to an agile R&D engine Agreement overviews for Zio
Read more →PGENPrecigen to Host Conference Call to Provide Business Updates Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON), and a biopharmaceutical company specializing in the development of...
GERMANTOWN, Md. , Dec. 24, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON ), and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today anno
Read more →PGENPrecigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T™ Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS) Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON), and a biopharmaceutical company specializing in the development of...
GERMANTOWN, Md. , Dec. 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON ), and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today anno
Read more →PGENIntrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen s Vision for Full Developmental Autonomy of its CAR-T Program Merck KGaA, Darmstadt, Germany, to assign its Chimeric Antigen Receptor T-c
Intrexon and Merck KGaA, Darmstadt, Germany, Announce Agreement Realizing Precigen s Vision for Full Developmental Autonomy of its CAR-T Program Merck KGaA, Darmstadt, Germany, to assign its Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon Intrexon to issue Merck KG
Read more →PGENIntrexon Announces Third Quarter 2018 Financial Results Quarterly GAAP revenues of $32.4 million and net loss attributable to Intrexon of $57.3 million including non-cash charges of $38.7 million Adjusted EBITDA of $(28.
Intrexon Announces Third Quarter 2018 Financial Results Quarterly GAAP revenues of $32.4 million and net loss attributable to Intrexon of $57.3 million including non-cash charges of $38.7 million Adjusted EBITDA of $(28.9) million GERMANTOWN, MD, November 8, 2018 Intrexon Cor
Read more →PGENIntrexon Announces Transfer of Stock Listing to Nasdaq Ticker symbol to remain
Intrexon Announces Transfer of Stock Listing to Nasdaq Ticker symbol to remain XON GERMANTOWN, MD, September 12, 2018 Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today a
Read more →PGENIntrexon Business Update and Conference Call GERMANTOWN, MD
Intrexon Business Update and Conference Call GERMANTOWN, MD, August 9, 2018 Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, will host a call today to provide a general update
Read more →PGENfor the purpose of incorporating the information set forth herein by reference into the automatic shelf registration statement on Form S-3ASR (File No. 333-220326) that was filed by the registrant with the Securities and
The registrant is filing this Exhibit 99.1 for the purpose of incorporating the information set forth herein by reference into the automatic shelf registration statement on Form S-3ASR (File No. 333-220326) that was filed by the registrant with the Securities and Exchange Commi
Read more →PGENPrecigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001 Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation and a biopharmaceutical company specializing in the development of innovative gene...
GERMANTOWN, Md. , May 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced the treatme
Read more →PGENIntrexon Announces First Quarter 2018 Financial Results Quarterly GAAP revenues of $43.8 million and net loss attributable to Intrexon of $42.0 million including non-cash charges of $26.3 million Adjusted EBITDA of $(19.
Intrexon Announces First Quarter 2018 Financial Results Quarterly GAAP revenues of $43.8 million and net loss attributable to Intrexon of $42.0 million including non-cash charges of $26.3 million Adjusted EBITDA of $(19.7) million GERMANTOWN, MD, May 10, 2018 Intrexon Corpora
Read more →PGENIntrexon Announces Fourth Quarter and Full Year 2017 Financial Results Quarterly GAAP revenues of $77.0 million and net loss attributable to Intrexon of $27.3 million including non-cash charges of $41.5 million Adjusted
Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results Quarterly GAAP revenues of $77.0 million and net loss attributable to Intrexon of $27.3 million including non-cash charges of $41.5 million Adjusted EBITDA of $13.7 million GERMANTOWN, MD, March 1, 2018 In
Read more →PGENConstruction of powerful gene expression programs drives efficacy Control of gene expression and regulation drives safety Delivery through cellular and non-viral based approaches increases applicability Enabling Targeted
J.P. Morgan Healthcare Conference January 10, 2018 Exhibit 99.1 Construction of powerful gene expression programs drives efficacy Control of gene expression and regulation drives safety Delivery through cellular and non-viral based approaches increases applicability Enabling T
Read more →PGENActoBio Therapeutics - Introduction A new class of microbe-based biopharmaceuticals (ActoBiotics ) for expression and local delivery of therapeutics at disease sites For oral, gastrointestinal, and autoimmune/allergic di
ActoBio Therapeutics , Inc. Pieter Rottiers, PhD, Chief Executive Officer January 2018 Industriepark 7C Building D, 9052 Gent Belgium Tel: +32 9 277 11 77 | E-mail: IA.info@intrexon.com Exhibit 99.1 ActoBio Therapeutics - Introduction A new class of microbe-based biopharmaceut
Read more →PGENIntrexon Corporation Annual CEO Letter GERMANTOWN, MD
Intrexon Corporation Annual CEO Letter GERMANTOWN, MD, January 2, 2018 Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet,
Read more →PGENIntrexon Announces Key Management Appointments GERMANTOWN, Md.
Intrexon Announces Key Management Appointments GERMANTOWN, Md., November 27, 2017 - Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology, today announced key executive promotions: All three will report to Chairman and Chief Executive O
Read more →PGENIntrexon Announces Third Quarter 2017 Financial Results Quarterly GAAP revenues of $46.0 million and net loss attributable to Intrexon of $39.7 million including non-cash charges of $24.0 million Adjusted EBITDA of $(16.
Intrexon Announces Third Quarter 2017 Financial Results Quarterly GAAP revenues of $46.0 million and net loss attributable to Intrexon of $39.7 million including non-cash charges of $24.0 million Adjusted EBITDA of $(16.4) million GERMANTOWN, MD, November 9, 2017 Intrexon Cor
Read more →PGENIntrexon Announces Second Quarter and First Half 2017 Financial Results Quarterly GAAP revenues of $54.4 million and net loss attributable to Intrexon of $18.7 million including non-cash charges of $17.4 million Adjusted
Intrexon Announces Second Quarter and First Half 2017 Financial Results Quarterly GAAP revenues of $54.4 million and net loss attributable to Intrexon of $18.7 million including non-cash charges of $17.4 million Adjusted EBITDA of $(2.0) million GERMANTOWN, MD, August 9, 2017
Read more →PGENIntrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition GERMANTOWN, Md.
Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition GERMANTOWN, Md., June 16, 2017 Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the p
Read more →PGENIntrexon Announces First Quarter 2017 Financial Results Quarterly GAAP revenues of $53.7 million and net loss attributable to Intrexon of $31.4 million including non-cash charges of $24.7 million Adjusted EBITDA of $(7.1
Intrexon Announces First Quarter 2017 Financial Results Quarterly GAAP revenues of $53.7 million and net loss attributable to Intrexon of $31.4 million including non-cash charges of $24.7 million Adjusted EBITDA of $(7.1) million GERMANTOWN, MD, May 10, 2017 Intrexon Corporat
Read more →PGENIntrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors Germantown, MD
Intrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors Germantown, MD, April 27, 2017 Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today annou
Read more →PGENIntrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health Assets Geno Germano to Step Down as President; Randal Kirk to Remain CEO Executive Search Underway to Lead Precigen
Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health Geno Germano to Step Down as President; Randal Kirk to Remain CEO Executive Search Underway to Lead Precigen Germantown, MD, March 10, 2017 Intrexon Corporation (NYSE: XON)
Read more →PGENIntrexon Announces Fourth Quarter and Full Year 2016 Financial Results Quarterly GAAP revenues of $46.0 million and net loss attributable to Intrexon of $44.1 million including non-cash charges of $38.9 million Adjusted
Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results Quarterly GAAP revenues of $46.0 million and net loss attributable to Intrexon of $44.1 million including non-cash charges of $38.9 million Adjusted EBITDA of $(5.8) million GERMANTOWN, MD, March 1, 2017 I
Read more →PGENIntrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform GenVec s AdenoVerse to be Integrated into Intrexon s Proprietary Synthetic Biology Platform GERMANTOWN, MD, and GAITHERSBURG, MD
Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform GenVec s AdenoVerse to be Integrated into Intrexon s Proprietary Synthetic Biology Platform GERMANTOWN, MD, and GAITHERSBURG, MD, Jan. 24, 2017 Intrexon Corporation (NYSE: XON), a leader in the enginee
Read more →PGENForward-Looking Statements Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor P
Geno Germano, President JP Morgan Healthcare Conference - January 11th, 2017 Exhibit 99.1 Forward-Looking Statements Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are m
Read more →PGENIntrexon Announces Third Quarter 2016 Financial Results Quarterly GAAP revenues of $49.0 million and net loss of $29.0 million including non-cash charges of $25.5 million Adjusted EBITDA (as redefined) of $(3.7) million
Intrexon Announces Third Quarter 2016 Financial Results Quarterly GAAP revenues of $49.0 million and net loss of $29.0 million including non-cash charges of $25.5 million Adjusted EBITDA (as redefined) of $(3.7) million Adjusted EBITDA (as previously defined) of $(5.6) million
Read more →PGENIntrexon Announces Second Quarter and First Half 2016 Financial Results Quarterly revenues of $52.5 million and GAAP net loss of $49.1 million including non-cash charges of $44.0 million Adjusted EBITDA of $110.7 million
Intrexon Announces Second Quarter and First Half 2016 Financial Results Quarterly revenues of $52.5 million and GAAP net loss of $49.1 million including non-cash charges of $44.0 million Adjusted EBITDA of $110.7 million GERMANTOWN, MD, August 9, 2016 Intrexon Corporation (NY
Read more →PGENIntrexon Appoints Dr. Andrew J. Last as Chief Operating Officer Germantown, MD
Intrexon Appoints Dr. Andrew J. Last as Chief Operating Officer Germantown, MD, August 8, 2016 Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the appointment
Read more →PGENIntrexon and ZIOPHARM Amend Exclusive Channel Collaborations to Improve Alignment as Programs Advance through Development Germantown, MD, and Boston, MA
Intrexon and ZIOPHARM Amend Exclusive Channel Collaborations to Improve Alignment as Programs Advance Germantown, MD, and Boston, MA June 30, 2016 Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical co
Read more →PGENIntrexon Announces Retirement of Samuel Broder, M.D., Head of Health Sector Broder Continuing as Consultant to the Company Germantown, MD
Intrexon Announces Retirement of Samuel Broder, M.D., Head of Health Sector Broder Continuing as Consultant to the Company Germantown, MD, June 6, 2016 Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the retirement of Samuel Broder, M.D., Senio
Read more →PGENIntrexon Appoints Geno Germano to New Role of President Germantown, MD, May 1 7 , 201 6 Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Geno Germano to the new role of
Intrexon Appoints Geno Germano to New Role of President Germantown, MD, May 17, 2016 Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Geno Germano to the new role of President of Intrexon effective June 1, 2016, reporting to Ch
Read more →PGENIntrexon Announces First Quarter 2016 Financial Results Quarterly revenues of $43.4 million and GAAP net loss of $64.4 million including non-cash charges of $50.6 million Adjusted EBITDA of $1.9 million Consideration rec
Intrexon Announces First Quarter 2016 Financial Results Quarterly revenues of $43.4 million and GAAP net loss of $64.4 million including non-cash charges of $50.6 million Adjusted EBITDA of $1.9 million Consideration received for technology access fees, reimbursement of R&D s
Read more →PGENIntrexon Establishes Crop Protection Enterprise Intrexon Crop Protection Intended to Become Standalone Public Company Davis, CA
Intrexon Establishes Crop Protection Enterprise Intrexon Crop Protection Intended to Become Standalone Public Company Davis, CA, May 4, 2016 Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the formation of Intrexon Crop Protection (ICP), a whol
Read more →PGENIntrexon Realigns Responsibilities, Augments Team GERMANTOWN, MD
Intrexon Realigns Responsibilities, Augments Team GERMANTOWN, MD, March 21, 2016 Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced a realignment of management responsibilities in response to the successful growth of the company, intensifying its f
Read more →PGENIntrexon Announces Fourth Quarter and Full Year 2015 Financial Results Quarterly revenues of $41.5 million and GAAP net loss of $32.7 million including non-cash charges of $19.4 million FY2015 Adjusted EBITDA of $53.4 mi
Intrexon Announces Fourth Quarter and Full Year 2015 Financial Results Quarterly revenues of $41.5 million and GAAP net loss of $32.7 million including non-cash charges of $19.4 million FY2015 Adjusted EBITDA of $53.4 million YTD consideration received for technology access f
Read more →PGENForward Looking Statements Special Note Regarding Forward-Looking Statements Some of the matters discussed in this presentation may constitute forward-looking statements within the meaning of the "safe harbor" provisions
INVESTOR DAY | NOVEMBER 12, 2015 Forward Looking Statements Special Note Regarding Forward-Looking Statements Some of the matters discussed in this presentation may constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securitie
Read more →PGENIntrexon Announces Third Quarter 2015 Financial Results Quarterly revenues of $53.4 million and GAAP net loss of $38.2 million Adjusted EBITDA of $3.8 million YTD consideration received for technology access fees, reimbu
Intrexon Announces Third Quarter 2015 Financial Results Quarterly revenues of $53.4 million and GAAP net loss of $38.2 million Adjusted EBITDA of $3.8 million YTD consideration received for technology access fees, reimbursement of R&D services and product and service revenues
Read more →PGENZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM Oncology, Inc. t
Graft-Versus-Host Disease Exclusive Channel Collaboration Forward-looking Statements contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities L
Read more →PGENEnvironmentally Friendly Insect Control Solutions Tackle Growing Global Health and Agriculture Problems with Unparalleled Accuracy Germantown, MD, and Oxford, England
Environmentally Friendly Insect Control Solutions Tackle Growing Global Health and Agriculture Problems with Unparalleled Accuracy Germantown, MD, and Oxford, England, September 8, 2015 Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today it has co
Read more →PGENfor the purpose of incorporating the information set forth herein by reference into the automatic shelf registration statement on Form S-3ASR (File No. 333-198598) that was filed by the registrant with the Securities and
The registrant is filing this Exchange Commission on September 5, 2014. The following table sets forth the estimated costs and expenses, other than underwriting discounts and commissions, payable by the registrant in connection with the sale of the securities being registered:
Read more →Competitive Position
How PGEN ranks across every disease it competes inCompetitive Position is a premium feature
See how PGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial